Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)

Multicenter, Phase 2 Clinical Trial Evaluating the Efficacy and Tolerability of Induction and Consolidation Chemotherapy Comprising Fludarabine, Cytarabine, and Attenuated-dose Idarubicin in Elderly Patients With AML(Acute Myeloid Leukemia)

A phase II clinical trial evaluating the efficacy and tolerability of induction and consolidation chemotherapy comprising Fludarabine, cytarabine and attenuated-dose Idarubicin (modified-FLAI) in the elderly patients with acute myeloid leukemia.

Inclusion Criteria:

• previously untreated AML (excluding acute promyelocytic leukemia)
• age greater than 60 years old
• ECOG PS (Eastern Cooperative Oncology Group Performance scale) less than 2
• adequate hepatic/ renal/ cardiac function

Exclusion Criteria:

• acute promyelocytic leukemia
• significant cardiac disease
• combined non-hematologic malignancy
• aleukemic leukemia (only granulocytic sarcoma)
• CNS (Central Nervous system) involvement
• significant comorbidity/ uncontrollable bleeding tendency